PAUL LARSEN: Open Payments
NPI 1720189749 · CHEWELAH, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$187 in 10 payments from 8 companies in 2025. Trend: 2023 $72 · 2024 $90 · 2025 $187
Food & beverage: $187
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| ABBVIE INC. | 2 | $32 |
| Dexcom, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $24 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
| PFIZER INC. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
Products named: JARDIANCE, Dexcom G6 Transmitter, Ozempic, JOURNAVX, UBRELVY, NURTEC ODT, FARXIGA, QULIPTA.
Industry payments across WA — which companies pay providers there.
